Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


Laura Marques de Azevedo

Laura Marques de Azevedo

University of São Paulo, Brazil

Title: Efficiency of the hypertension line of care for the reduction of cardiovascular risk


Biography: Laura Marques de Azevedo


The line of care (LC) is defined as a set of knowledge and resources those are needed to cope with specific conditions in the life cycle. The hypertension has a specific LC, named HLC and the great challenge consists on the reduction of the cardiovascular risk classification of the patients. This study was done to demonstrate the efficiency of the HLC. A cross-sectional descriptive study was performed in a Brazilian basic health care unit. The data were collected between January and October of 2017. The sample was composed of 28 users those were hypertension carriers, having an inclusion criteria for the registration in the HLC in January 2017 and has a ‘very high additional risk’ classification on the occasion of its inclusion in the HLC. The results showed a progressive decrease in cardiovascular risk. There was a reduction of 82.15% (N=23) of the ‘very high additional risk’ ratings. It is inferred that the reduction was not greater due to the risks that could not be controlled or excluded from the classification metrics like prior cardiovascular events and acute myocardial infarction. These users were downgraded to high risk 53.57% (N=15) and moderated risk 28.57% (N=8). It is observed a greater adhesion of the patients to the medical and nursing consultations, educational group of the HLC and to the Singular Therapeutic Project. It is concluded that the HLC is effective in reducing the very high cardiovascular additional risk classification of the follow-up users, contributing significantly to the reduction of morbimortality in hypertension users.